SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias
Objective: This study was designed to explore in Parkinson’s disease (PD) the role of dopamine transporter (DAT)-specific single photon emission computed tomography (SPECT) imaging as a…Wearable motion quantification and electronic diaries for long-term monitoring of Parkinson’s disease
Objective: To clinically assess wearable motion sensors for measuring tremor, dyskinesia, slowness, and mobility and an electronic diary for Parkinson’s disease (PD) Background: A patient…The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of highly-selective metabotropic glutamate 2 receptor (mGluR2) activation at alleviating and preventing the development of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Chronic…Anosognosia for Levododopa-induced Dyskinesias in PD – Frequency
Objective: To evaluate the factors and possible mechanisms associated with anosognosia for LIDs in patients with PD using movie presentations and mirrored self-images. Background: Levodopa-induced…The Personal Kinetigraph Fluctuator Score Identifies Motor Fluctuations in Parkinson’s disease
Objective: To evaluate the Personal Kinetigraph (PKG) fluctuator score (FS) in detecting motor fluctuations in Parkinson's disease (PD) patients. Background: Fluctuations of response to levodopa,…The highly-selective metabotropic glutamate receptor 2 positive allosteric modulator LY-487,379 alleviates psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset
Objective: To investigate the effect of metabotropic glutamate receptor 2 (mGluR2) activation on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset…Design and personalisation of new upper-limb dynamic orthoses for dystonia and dyskinesia
Objective: The study proposes a method to obtain anatomically- and functionally-personalised orthotics for the dynamic postural control of the upper limb. Background: The orthotic treatment…Is there a significant relationship between weight loss and prevalence of side effects of Parkinsonian medication? A retrospective, single-centre analysis, South Wales, UK.
Objective: To investigate if there is a significant relationship between weight loss in persons with Parkinson’s disease and side-effect incidence, and if so to what…Tremor as the first symptom reported by Parkinson’s disease patients is a predictor of future motor subtype and levodopa-induced dyskinesia.
Objective: To better delineate risk profiles for the development of levodopa-induced dyskinesia is an important effort that can help understand this phenomenon and could impact…Tremor-Dominant Clinical Phenotype is Associated with Low Risk of Levodopa-Induced Dyskinesia in Parkinson’s Disease
Objective: To evaluate possible associations between epidemiological and clinical data with risk of levodopa-induced dyskinesias (LID) onset in Parkinson’s disease (PD) patients. Background: LID are…
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 49
- Next Page »